Edgar Filing: AETHLON MEDICAL INC - Form 8-K

AETHLON MEDICAL IN Form 8-K February 11, 2019	C	
UNITED STATES		
SECURITIES AND EXC	HANGE COMMISSION	
Washington, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or	15(d)	
of the Securities Exchang	e Act of 1934	
Date of Report (Date of ear	liest event reported): <b>Februa</b>	ry 11, 2019
Aethlon Medical, Inc.		
(Exact name of registrant a	s specified in its charter)	
Nevada (State or other jurisdiction of incorporation)	<b>001-37487</b> (Commission File Number)	13-3632859 (IRS Employer Identification No.)
9365 Granite Ridge Drive	, Suite 100	02122
San Diego, California (Address of principal execu	ative offices)	<b>92123</b> (Zip Code)

 $Registrant's \ telephone \ number, including \ area \ code: 858-459-7800$ 

Not applicable

### Edgar Filing: AETHLON MEDICAL INC - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

	Item 2.02	Results of O	perations and	<b>Financial</b>	Condition
--	-----------	--------------	---------------	------------------	-----------

On February 11, 2019, Aethlon Medical, Inc. (the "Registrant") issued a press release announcing its financial results for the third quarter ended December 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1.

The information provided in this Item 2.02 of this Current Report on Form 8-K, including the exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of the Registrant dated February 11, 2019.

# Edgar Filing: AETHLON MEDICAL INC - Form 8-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## Aethlon Medical, Inc.

Dated: February 11, 2019 By: /s/ James B. Frakes

James B. Frakes

Chief Financial Officer